mCRPC in focus
How will emerging clinical trial data impact available treatment strategies for metastatic castration-resistant prostate cancer (mCRPC)? See expert analysis on:
- Key findings from the latest mCRPC trials, with Dr Alexander Chehrazi-Raffle
- Reasons for the low uptake of guideline recommendations for mCRPC management in practice, with Professor Axel Merseburger
- The implications of new data presented at 2024 ASCO conferences, in a roundtable discussion with Dr Neeraj Agarwal, Professor Merseburger, Professor Karim Fizazi, and Dr Bárbara Vieira Lima Aguiar Melão
ASCO GU 2025: mPC latest
Radioligand therapies in mPC
Roundtable: mCRPC update 2024
Analysis of trials on current and emerging treatments
Expert opinions on mCRPC management
Insights on mCRPC treatments, guideline barriers, patient populations, and trial designs from Professors Axel Merseburger and Neeraj Agarwal
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.
of interest
are looking at
saved
next event